Eli Lilly aims to ramp up social media presence
The drugmaker recently drafted social media guidelines it hopes can help it expand its use of social media to more of its employees—without running afoul of regulators.
The drugmaker recently drafted social media guidelines it hopes can help it expand its use of social media to more of its employees—without running afoul of regulators.
The torrent of competitors’ humorous TV commercials forced Indiana Farm Bureau Insurance to roll out its own campaign. So far, its “Knock on Wood” shtick is said to have boosted brand awareness in urban markets by 12 percent, as measured by social media chatter.
Eli Lilly and Co. said Thursday that its cancer drug Alimta didn’t extend overall survival when combined with Roche Holding AG’s Avastin in patients with a form of lung tumor.
Indianapolis-based WellPoint Inc., the second-biggest U.S. health insurer, is planning a four-part debt offering to help fund its $4.9 billion acquisition of Amerigroup Corp, the insurer said Wednesday.
Carmel-based insurer CNO Financial Group Inc. said Tuesday that it is seeking $950 million of loans and bonds to repay debt and reduce borrowing costs.
Indianapolis-based St. Vincent Health will manage operations at Monroe Hospital in Bloomington under an agreement announced on Tuesday. Monroe gives St. Vincent a line of hospitals stretching from Indianapolis to Bedford and even farther south to Salem and Evansville.
Investors who called strongly for the head of WellPoint Inc. CEO Angela Braly got what they wanted last week. In response, they bid up WellPoint's share price by $1.4 billion on the day after she resigned.
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
An Indiana University study has found that what people studied in college had a direct effect on their chances of employment during the Great Recession.
Indianapolis-based drugmaker Eli Lilly and Co. said Thursday its general counsel, Robert Armitage, will retire at the end of the year and be replaced by deputy general counsel Michael Harrington.
Janssen Pharmaceuticals Inc. and parent company Johnson & Johnson on Thursday announced a $181 million settlement with 36 states, including Indiana, and the District of Columbia over charges of marketing anti-psychotic drugs for non-approved uses.
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
WellPoint Inc. is expected to give about $15 million in cash, stock and benefits to former CEO Angela Braly on her way out the door, based on the terms of a separation agreement filed by the company Wednesday morning. And the payout could be even more lucrative based on the company’s future stock price.
Investors are looking for a CEO who can right the Indianapolis-based company’s financial performance and integrate WellPoint’s recent deals to buy Medicaid insurer Amerigroup Corp. and vision company 1-800-Contacts Inc.
A southwestern Indiana cantaloupe farm is the source of at least some of the salmonella responsible for an outbreak that sickened people in 21 states and killed two Kentucky residents, the Food and Drug Administration said Tuesday.
The Cancer Care Group in Indianapolis said a laptop computer bag containing private information on as many as 55,000 patients has been stolen.
Democratic gubernatorial candidate John Gregg says he likely would support a hybrid health insurance exchange for Hoosiers if elected in November.
After Eli Lilly and Co. found a “glimmer of hope” in its test of its experimental Alzheimer’s drug, doctors and stock analysts generally concluded the company needs to conduct another long clinical trial to prove the drug’s effect. But one stock analyst thinks Lilly already has what it needs to ask for approval for its drug.
There’s more than political philosophy at stake as Indiana’s candidates for governor wrestle over whether the state should start its own health insurance exchange. There’s potentially a lot of money for low- and moderate-income Hoosiers at stake, too.
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.